Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- AirbnbAirbnb.org and Greece’s Ministry of Health partner to Provide Housing for Doctors and Nurses on Five Aegean IslandsCompanies: AirbnbAirbnb.org, a nonprofit founded by Airbnb to provide emergency housing in times of crisis, and Greece's Ministry of Health announced a new pilot partnership to provide free stays for doctors and nurses working at Public Health Centers on five Greek islands during the high-demand summer season, when local housing shortages make it difficult for essential medical staff to find affordable places to live near their posts. The post Airbnb.org and Greece’s Ministry of Health partner to Provide Housing for Doctors and Nurses on Five Aegean Islands appeared first on Airbnb Newsroom.
- BayerBayer submits application for next indication of Kerendia in ChinaCompanies: BayerBayer today announced the submission of a New Drug Application to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), seeking approval to extend the indication of finerenone in China to include adult patients with non-diabetic chronic kidney disease. The regulatory submission is supported by the positive results from the Phase III FIND-CKD study, which were presented at ERA Congress 2026 and simultaneously published in the New England Journal of Medicine. Approximately 850 million people worldwide are living with chronic kidney disease (CKD) and more than half of them have non-diabetic CKD. Worldwide, more than 3.5 million people with kidney failure are treated with dialysis, which is associated with a 5-year survival rate of about 40% after treatment initiation. Non-diabetic CKD can have a range of etiologies, of which the most common include kidney disease linked to hypertension and glomerulonephritis (including IgAN and FSGS). Despite standard of care, patients with non-diabetic CKD remain at risk for kidney failure and cardiovascular events. Chronic kidney disease linked to hypertension is the second most common cause of kidney failure. In addition, patients with advanced non-diabetic CKD face a significantly increased risk for a fatal cardiovascular event, about 2.6 times higher than that of the general population without CKD, which increases further as kidney function declines. “People living with non-diabetic chronic kidney disease (CKD) face a substantial risk for progressive kidney function decline and cardiovascular events. The FIND-CKD study adds robust evidence supporting the potential of finerenone to address this risk across a diverse range of non-diabetic CKD etiologies, including CKD due to hypertension and glomerular diseases,” said Dr. Christian Rommel, Global Head of Research and Development at Bayer’s Pharmaceuticals Division. “Building on the evidence generated across the finerenone clinical development program, the submission of these data marks an important step in our efforts to bring finerenone to more patients who may benefit from its cardio-kidney protective effects and reflects our commitment to advancing innovation for people living with heart and kidney diseases worldwide.” Since 2021, finerenone has been marketed as Kerendia™ or, in selected countries, as Firialta™, and approved for the treatment of adult patients with CKD associated with type 2 diabetes (T2D) in more than 100 countries worldwide, including in China, Europe, Japan, and the U.S. Finerenone is also approved for the treatment of heart failure with left ventricular ejection fraction (LVEF) ≥ 40% in the U.S., the EU, in Japan, and in China, with additional applications under regulatory review. About Kerendia™ / Firialta™ (finerenone) Kerendia™ and Firialta™ are globally protected trademarks for finerenone. Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway that in five pivotal Phase III studies has demonstrated cardiovascular and/or kidney benefits across a broad range of patient populations, including patients with HF with left ventricular ejection fraction (LVEF) ≥40%, patients with CKD associated with type 2 diabetes, patients with CKD associated with type 1 diabetes, and patients with non-diabetic CKD. Finerenone is a selective, non-steroidal mineralocorticoid receptor antagonist (nsMRA) that has been shown to block harmful effects of MR overactivation. MR overactivation contributes to chronic kidney disease (CKD) progression and cardiovascular damage which can be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors. The clinical study program with finerenone, FINEOVATE, currently comprises twelve Phase III studies with dedicated programs in CKD and HF respectively. The THUNDERBALL CKD program consists of the completed Phase III studies FIDELIO-DKD, FIGARO-DKD, FIND-CKD, and FINE-ONE, and the Phase II study CONFIDENCE; as well as the ongoing Phase III studies in pediatric patient populations FIONA, and FIONA-OLE. The MOONRAKER program includes the completed pivotal Phase III study FINEARTS-HF, the ongoing investigator-sponsored, collaborative studies REDEFINE-HF, CONFIRMATION-HF, and FINALITY-HF, as well as the ongoing Phase III studies in pediatric patient populations, FIORE and FIORELLO. About FIND-CKD FIND-CKD is the largest Phase III study to date focused on non-diabetic CKD. The study investigated finerenone in a broad patient population spanning different etiologies of non-diabetic CKD, adding to the positive data and breadth of evidence of finerenone in CKD associated with diabetes. FIND-CKD (FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease) investigated the efficacy and safety of finerenone compared to placebo in addition to standard of care in more than 1,500 patients with non-diabetic chronic kidney disease etiologies, including kidney disease linked to hypertension and glomerular diseases. Patients were randomized to receive either finerenone 10mg or 20mg or placebo on top of maximum tolerated labeled doses of a renin-angiotensin system (RAS)-blocking therapy such as an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB). In the FIND-CKD study, finerenone showed a statistically significant and clinically meaningful improvement of kidney function compared with placebo: The mean annual decline in eGFR from baseline to 32 months (total slope) was −4.0 ml/minute/1.73 m2/year with placebo and −3.3 ml/minute/1.73 m2/year with finerenone, corresponding to a 0.7 ml/minute/1.73 m2/year slower decline with finerenone [95% CI, 0.3-1.1; p Finerenone was well-tolerated in the FIND-CKD study, which is consistent with the well-established safety profile of finerenone. About Chronic Kidney Disease Chronic kidney disease (CKD) is a common and potentially deadly condition that is widely underrecognized. CKD progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced. Chronic Kidney Disease (CKD) represents a major global health challenge, affecting 850 million people worldwide – in fact, as the ninth leading cause of death, it results in 1.5 million fatalities each year, translating to one death every 20 seconds. In the U.S., 1 in 3 adults is at risk for the disease. At advanced stages of CKD, patients may need dialysis or a kidney transplant to stay alive. Healthy kidneys act as the body’s filter, removing waste products from the blood. They also control how much water and electrolytes are in the body, regulating blood pressure. As kidney function goes down, patients may experience a range of symptoms including leg swelling, tiredness in the day, nausea, muscle cramps, joint pain and confusion, trouble focusing, memory problems. Major underlying causes of CKD include diabetes, hypertension, and glomerular diseases such as immunoglobulin A nephropathy, focal segmental glomerulosclerosis and membranous nephropathy. About Bayer’s Commitment in Cardiovascular and Kidney Diseases Bayer is a leader in the area of cardiology and is advancing a portfolio of innovative treatments. The heart and the kidneys are closely linked in health and disease, and Bayer is working on new treatment approaches for cardiovascular and kidney diseases with high unmet medical needs. The strategy is to unlock the strong potential of the future cardiovascular market by transforming Bayer’s portfolio into precision cardiology, addressing the high disease burden, and driving long-term growth. Bayer’s portfolio already includes several innovative products and compounds in various stages of preclinical and clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cardiovascular and kidney diseases are treated. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Find more information at https://pharma.bayer.com Follow us on Facebook: http://www.facebook.com/bayer Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.
- GSKCabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026Companies: GSKSuperiority data from LATA together with OPERA findings add to the clinical and real-world evidence base for long-acting injectable Cabenuva
- GSKGSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UKCompanies: GSKInvestment further integrates company into world-class ecosystem of biomedical research, patient care and academia
- GSKGSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in ChinaCompanies: GSKARTEMIS-011, a phase III study conducted for China, met its primary endpoint of progression-free survival in relapsed osteosarcoma
- SanofiSanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviewsCompanies: SanofiSanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews Paris, July 24, 2026. Sanofi today announced the discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis (AD). This decision not to submit for global regulatory reviews was made as part of an ongoing strategic assessment of the pipeline. San
- Samsung[Infographic] [Galaxy Unpacked July 2026] Highlights From Galaxy UnpackedCompanies: Samsung ElectronicsOn July 22, Samsung Electronics hosted Galaxy Unpacked July 2026 at Old Billingsgate in London — unveiling its next-generation foldables with agentic AI. Alongside Galaxy Z Fold8 Ultra, Galaxy Z Fold8 and Galaxy Z Flip8, Samsung introduced Galaxy Watch Ultra2 and Galaxy Watch9 with more advanced health features, as well as intelligent eyewear. Through a […]
- Samsung[Galaxy Unpacked July 2026] Samsung and Partners Envision a Connected Care Future — From First Signal to Lasting ChangeCompanies: Samsung ElectronicsAt Galaxy Unpacked July 2026 in London, Samsung Electronics set out its vision for the next chapter of digital health — a future where care moves from reactive treatment toward preventive, personalized and connected experiences, supported by trusted health innovation and partnerships across the healthcare ecosystem. To explore that vision, Samsung hosted a Health Forum […]
- OpenAILaunching Health in ChatGPTCompanies: OpenAIHealth in ChatGPT now lets eligible U.S. users securely connect medical records and Apple Health to get more personalized insights and better understand their health.
- Samsung[Galaxy Unpacked July 2026] A First Look at Galaxy Watch Ultra2 and Galaxy Watch9Companies: Samsung ElectronicsAt Galaxy Unpacked July 2026 in London, Samsung Electronics unveiled Galaxy Watch Ultra2 and Galaxy Watch9, expanding the digital health experience on the wrist. From the moment users wake up to the time they finish a workout and begin recovery, a smartwatch stays in contact with the body throughout the day. Samsung Newsroom got an […]
- SamsungSamsung Galaxy Watch Ultra2 and Watch9: Your Health Companion on the WristCompanies: Samsung ElectronicsSamsung Electronics today announced the all-new Galaxy Watch Ultra2 and Galaxy Watch9, delivering a new era of effortless health, where users can unlock in-depth, meaningful health insights simply by wearing these devices. To support 24/7 wearability, Samsung delivers powerful innovations that maximize comfort while advancing performance with Galaxy Watch’s largest battery and brightest display ever, […]
- SamsungSamsung Launches Health Assistant Beta, First Fully Integrated AI-Powered Personal Health AssistantCompanies: Samsung ElectronicsSamsung Health Assistant, a fully integrated AI-powered personal health assistant for Samsung Health, is now available in beta for eligible U.S. users. Health Assistant will help users achieve their health and wellness goals by connecting important health data with insights that empower them to ask questions about their health and gain access to rich, personalized […]